Laura Elizabeth Lansdowne
Managing Editor
As managing editor, Laura works closely with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She plays an active part in the general oversight and training of the in-house editorial team, as well as working directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.
Latest Content
News
Fetal Gene Therapy Prevents Lethal Neurodegenerative Disease
Researchers have successfully prevented the development of a fatal neurodegenerative disorder, Gaucher disease, using fetal gene therapy, in mice. The study highlights the potential of using this approach to combat lethal neurodegenerative diseases affecting newborns.
News
Survival Rates Double for Patients with Melanoma Brain Metastases Receiving Immunotherapy
Checkpoint blockade immunotherapies significantly improve the survival of patients with melanoma brain metastases, according to a new study.
Article
Creating Innovative Tools to Solve Complex Problems
With 15 issued US patents, 45 published patent applications and nearly 50 refereed publications, Michael Weiner, PhD, Vice President, Molecular Sciences at Abcam is an expert in molecular biology. We recently spoke with Michael to learn more about the specific inspirations that ignited his interest in science. He tell us more about his research interests and the molecular biology methods that he has invented over the years.
Industry Insight
Supporting the Development of Regenerative Medicines
Regenerative medicine is a branch of translational research which focuses on methods to regrow, repair or replace human cells, tissues or organs. We recently spoke with Michael May, President & CEO of CCRM, an organization supporting the development of regenerative medicines and associated technologies to learn more about their latest projects and collaborations.
Industry Insight
Developing Bispecific Antibodies
Bispecific antibodies (bsAbs) harness the specificities of two antibodies and combine them to simultaneously recognize different antigens or epitopes. This ‘two-target’ functionality has meant that interest in their use for therapeutic applications has increased considerably. We spoke to GenScript’s Liusong Yin, PhD, and Jie Ma, to learn more about bispecific antibodies and the associated challenges developing them.
Industry Insight
Targeting Cancer’s Metabolic Vulnerability with IACS-10759, a Small Molecule Drug
Cancer cells are able to evolve to depend on two metabolic processes, glycolysis and oxidative phosphorylation. We spoke to Phil Jones from The University of Texas MD Anderson Cancer Center, to learn about the discovery and development of IACS-10759, identified as as a viable oxidative phosphorylation inhibitor.
Industry Insight
Determining Prognostic Significance of Biomarkers for Risk Stratification of Early Stage Lung Cancer
During this year’s AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the team’s most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.
Industry Insight
Antibody Engineering: Driving Therapeutic Discovery and Diagnostics Forward
We recently spoke to GenScript’s VP of Marketing, Eric Wang, to learn more about the company’s mission to “make people and nature healthier through biotechnology”. Eric discusses the key phases of antibody therapeutic discovery and development, GenScript’s role in advancing drug discovery research, and tells us about the company’s recently launched custom rabbit monoclonal antibody service.
Article
The Role of Wnt Signaling in Cancer
Aberrant Wnt signaling has also been identified as a key mechanism in cancer biology. This article summarizes both the canonical (β-catenin dependent) and non-canonical (β-catenin independent) signaling pathways. It also highlights the role of Wnt signaling in numerous cancers and discusses novel approaches to targeting the pathway.
Industry Insight
The STING Pathway and Cancer
刺(干扰素刺激基因)是一个关键的我diator of innate immunity and the STING pathway has been shown to be involved in the induction of an anti-tumor immune response. We recently spoke to Andrea van Elsas, PhD, Chief Scientific Officer at Aduro Biotech to learn more about the company’s expertise in STING Pathway Activator technology.
Advertisement